← All news
Markets
Amgen stock surges on positive Sjögren’s trial results
2 outlets - including Investing and Biopharmadive - are covering this story. Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.
Covered by 2 outlets
All coverage · 4 articles
Investing.com Canada
·Sep 23, 10:16 UTC
Oppenheimer reiterates Amgen stock rating on positive trial data
BioPharma Dive
·Sep 22, 18:31 UTC
Amgen reports a Phase 3 win with Sjögren’s drug candidate
Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.
Investing.com UK
·Sep 22, 13:24 UTC
Amgen stock surges on positive Sjögren’s trial results
Investing.com Stock Market
·Sep 22, 13:22 UTC